Make Informed Investment Decisions with Affordable Access to Experts
Exploring the market potential of Jazz Pharma's Vyxeos (cytarabine and daunorubicin liposome for injection) in treating AMLTicker(s): JAZZ
Name: Dr Celalettin Ustun - MD
Institution: University of Minnesota)
- Medical Oncologist and Hematologist & Associate Professor of Medicine, Division of Hematology, Oncology and Transplantation at University of Minnesota.
- Currently manages 40 patients with AML and prescribes Vyxeos.
- Clinical interest in hematologic malignancies and hematopoietic cell transplant ad his research interest is in the conduct of clinical trials and the characterization of infectious complications of hematologic malignancy care.
Please describe your current practice. How many patients do you currently treat with AML?Added By: c_admin
How do you stratify your AML patients (ex.by young patients versus greater than 60, patients who are fit, or unfit). How you're currently treating those patient groups?Added By: c_admin
On a scale of 1-10, where would you rate your level of excitement for Vyxeos with 10 being very excited?Added By: c_admin
Is there anything else that you think is relevant in terms of treatments on the horizon that you're very excited about?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.